Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares

by · The Markets Daily

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the transaction, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

  • On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00.
  • On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25.
  • On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total transaction of $597,500.00.
  • On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Price Performance

NASDAQ:VERA traded up $0.42 during mid-day trading on Friday, hitting $42.47. 1,022,910 shares of the company’s stock traded hands, compared to its average volume of 870,480. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market cap of $2.69 billion, a PE ratio of -16.27 and a beta of 1.08. The firm’s 50 day simple moving average is $45.27 and its 200 day simple moving average is $40.47. Vera Therapeutics, Inc. has a 1 year low of $14.20 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). Sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on VERA. Wedbush increased their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank began coverage on Vera Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Guggenheim increased their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $59.22.

Check Out Our Latest Stock Analysis on Vera Therapeutics

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Vera Therapeutics by 28.5% during the 2nd quarter. Renaissance Technologies LLC now owns 147,800 shares of the company’s stock worth $5,347,000 after purchasing an additional 32,800 shares in the last quarter. First Turn Management LLC raised its position in shares of Vera Therapeutics by 53.3% in the third quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock valued at $14,431,000 after buying an additional 113,550 shares during the last quarter. Magnetar Financial LLC purchased a new position in shares of Vera Therapeutics during the second quarter valued at approximately $652,000. Lord Abbett & CO. LLC boosted its position in Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after acquiring an additional 124,197 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in Vera Therapeutics by 202.4% in the 2nd quarter. Victory Capital Management Inc. now owns 33,707 shares of the company’s stock worth $1,220,000 after acquiring an additional 22,560 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Featured Articles